Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Executive Summary

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.

You may also be interested in...



Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel